Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · Roundhill

Horizon Kinetics Medical ETF (MEDX)

Ticker MEDX · Since 1999-09-30 · · Holdings as of Jun 30, 2026

Expense ratio
0.85%$85/yr per $10k
5-yr return
+5.8%annualized
1-yr return
+28.4%as of Dec 2025
Net assets
$19.1Mall share classes
Holdings
33

Bottom line

Is MEDX a good fund? The bottom line

MEDX is an actively managed health care sector ETF from Roundhill.

Its expense ratio is 0.85% — about $85 a year on every $10,000 invested, cheaper than 57% of health care sector funds we track.

It returned +28.4% over one year, +5.8% a year over five years, +5.7% a year over ten (as of Dec 31, 2025, per its prospectus).

With $19.1 million in net assets and 33 holdings, its largest position is Eli Lilly & Co (18.5%) and the top 10 make up 72.4% of the portfolio.

What stands out

  • 5-year return beat 70% of category peers

What to watch

  • Concentrated: top 10 holdings are 72.4% of assets
  • Small fund ($19.1 million) — small funds are likelier to close

Updated Nov 19, 2026

What MEDX invests in

Horizon Kinetics Medical ETF ( Medical ETF or the Fund) seeks to provide long-term growth of capital.

The Fund is an actively managed exchange-traded fund (ETF) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and International Depositary Receipts (IDRs)) of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis toward companies engaged in cancer research and drug development, such as pharmaceutical development companies, surgical and medical instrument manufacturers and developers, pharmaceutical manufacturers, and biotech and medical research companies. These types of…

From the fund's prospectus (filed Apr 27, 2026).

MEDX performance

Fund calendar-year total returns, 2016–2025 2016: −8.0%; 2017: +10.7%; 2018: +1.7%; 2019: +16.0%; 2020: +9.0%; 2021: +10.6%; 2022: +4.2%; 2023: −6.0%; 2024: −4.7%; 2025: +28.4% −8% 2016 +11% 2017 +2% 2018 +16% 2019 +9% 2020 +11% 2021 +4% 2022 −6% 2023 −5% 2024 +28% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
MEDX+28.4%+5.8%+5.7%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full MEDX performance history →

What MEDX costs

On a $10,000 investment, MEDX's 0.85% expense ratio costs about $85 a year. The prospectus estimates $1,049 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full MEDX fee table →

MEDX top 10 holdings

#Holding% of fund
1Eli Lilly & Co LLY18.46%
2US Bank Mmda - Usbgfs 79.19%
3AbbVie Inc ABBV8.85%
4Novartis AG NVS6.89%
5Johnson & Johnson JNJ5.59%
6Alkermes PLC ALKS5.53%
7AstraZeneca PLC AZN4.98%
8Ionis Pharmaceuticals Inc IONS4.53%
9Bristol-Myers Squibb Co BMY4.42%
10Merck & Co Inc MRK3.96%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 72.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to MEDX

More funds like MEDX →

MEDX FAQ

What is the expense ratio of MEDX?
MEDX's expense ratio is 0.85%, which works out to about $85 a year for every $10,000 invested. The prospectus estimates total costs of $1,049 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MEDX a good investment?
It depends on your goals, but the data points to: 5-year return beat 70% of category peers; concentrated: top 10 holdings are 72.4% of assets; small fund ($19.1 million) — small funds are likelier to close. This is general information, not personalized advice.
What does MEDX hold?
MEDX's largest holdings are Eli Lilly & Co (18.5%), US Bank Mmda - Usbgfs 7 (9.2%), AbbVie Inc (8.9%), Novartis AG (6.9%), Johnson & Johnson (5.6%). It holds 33 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MEDX's 5-year return?
MEDX returned +5.8% a year over the five years ending Dec 31, 2025, and +5.7% a year over ten years. Past performance does not guarantee future results.
Who manages MEDX?
MEDX is offered by Roundhill through Listed Funds Trust.